NuProbe Forms Scientific Advisory Board and Appoints New Director
July 24, 2018
CAMBRIDGE, Mass. – July 24, 2018 — NuProbe Global, an…
Read More
A breakthrough molecular strategy
NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world’s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.
Latest News
NuProbe Announces $11 Million Series A Funding Round
April 23, 2018
Molecular diagnostics startup to expand reach of precision medicine. CAMBRIDGE,…
格微基因(NuProbe)1100万美元的A轮融资
April 23, 2018
贝壳社 6小时前 贝壳社今天获悉，早期分子诊断公司格微基因(NuProbe)筹集了1100万美元用来继续开发可用于癌症和传染病检测的，超灵敏，无创血液检测技术。此次A轮融资是由红杉资本中国基金和思嘉建信基金共同领投。其他投资者还包括药明康德风投基金。 这笔融资将用于扩大美国和中国的团队，以及继续进行技术开发，临床试验，和商品化。 格微基因以Toehold Probe为基础的技术是在哈佛大学维斯生物工程研究所和莱斯大学进行的初始研究和开发，并得到其专利授权。这是一项突破性的分子技术，可用于检测包括癌症在内的多种疾病。格微基因的技术可以非常灵敏的识别早期阶段的突变体，它能提高疾病检出率，并帮助指导可增加患者生存机会的治疗决策。 格微基因联合创始人，同时也是维斯研究所和哈佛医学院的系统生物学教授尹鹏博士表示 “格微基因的愿景是开创技术创新以促进人类健康。其核心技术能够有效探测细微的疾病特征，例如癌症中稀有的突变。 我们希望通过技术创新以扩大精准医疗的适用范围。” 在临床预试验中，格微基因的技术将qPCR和NGS突变检测灵敏度改善了10－100倍，达到0.01%，…
Global Founders
David Yu Zhang, Ph.D.
David Zhang, Ph.D., is the Ted Law Jr. Assistant Professor of Bioengineering at Rice University. He is a leading expert in molecular diagnostics and DNA biotechnology, and maintains active collaborations with multiple biotech companies.
Victor Chenyang Shi, Ph.D.
Victor Shi, Ph.D., is a seasoned business executive, entrepreneur, and investor in diagnostics and biotech industry. He was the Founding President of Qiagen Asia Pacific and a former Professor at National University of Singapore.
Scientific Advisory Board
George M. Church, Ph.D.
George M. Church, Ph.D., is a Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard and MIT, and a Founding Member of the Wyss Institute for Biologically Inspired Engineering at Harvard. Dr. Church is also Director of the U.S. Department of Energy Technology Center, Director of the National Institutes of Health Center of Excellence in Genomic Science, and Director of the Personal Genome Project. His is the co-founder of more than 15 biotech companies including AbVitro, Editas Medicine, Veritas Genetics, Warpdrive Bio, eGenesis and ReadCoor. He is a member of the National Academy of Sciences, the National Academy of Engineering and the Franklin Bower Laureate for Achievement in Science. He received a B.A. in Zoology and Chemistry from Duke University and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.
- More
David R. Walt, Ph.D.
David R. Walt, Ph.D., is a member of the faculty at Harvard Medical School in the Department of Pathology at Brigham and Women’s Hospital, is a Member of the Wyss Institute, and is a Howard Hughes Medical Institute Professor. Previously, he was University Professor at Tufts University. Dr. Walt is the Scientific Founder of Illumina Inc. and Quanterix Corp. and has co-founded several other life sciences startups including Ultivue, Inc. and Arbor Biotechnologies. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a B.S. in Chemistry from the University of Michigan and a Ph.D. in Chemical Biology from SUNY at Stony Brook.
- More
OUR INVESTORS
Technology
NuProbe technology utilizes DNA toehold probe systems based on the fundamental engineering principle of molecular competition and precisely balanced thermodynamics and its application to rare allele detection.
Toehold probe design achieves near optimal specificity and is robust against environmental variation. Toehold probe designs improved qPCR and NGS mutation detection by 10-100 fold with sensitivity down to 0.01 percent and multiplexing capability of 10-100 multiplexed reactions with hundreds of mutations in the same test tube, enabling non-invasive early stage cancer cell-free DNA detection in blood plasma. We validated the technology with US patient samples, and are in the process of conducting preliminary clinical trials in China.
PCR
Nuprobe’s toehold probe designs improved qPCR mutation detection by 100 fold with sensitivity down to 0.01% with 10 validated multiplexing capabilities. This technology is verified with blood plasma samples from cancer patients.
Sequencing
NuProbe’s proprietary toehold probe technology provides an economic Sample-In Answer-Out (SIAO) solution in which cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations are integrated.
NGS
NuProbe’s unparalleled targeted variant enrichment probe set enables much greater sensitivity and higher sample throughput for next generation sequencing (NGS).